4//SEC Filing
Wingrove Theresa 4
Accession 0001104659-24-014705
CIK 0000855654other
Filed
Feb 11, 7:00 PM ET
Accepted
Feb 12, 4:41 PM ET
Size
33.7 KB
Accession
0001104659-24-014705
Insider Transaction Report
Form 4
ImmunoGen, Inc.IMGN
Wingrove Theresa
VP of Regulatory Affairs
Transactions
- Disposition to Issuer
Stock Option (Right to Buy)
2024-02-12−87,500→ 0 totalExercise: $9.01Exp: 2028-02-07→ Common Stock (87,500 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2024-02-12−16,666→ 0 totalExercise: $3.05Exp: 2026-07-18→ Common Stock (16,666 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2024-02-12−48,000→ 0 totalExercise: $16.72Exp: 2025-07-13→ Common Stock (48,000 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2024-02-12−9,267→ 0 totalExercise: $10.79Exp: 2024-07-17→ Common Stock (9,267 underlying) - Disposition to Issuer
Restricted Stock Unit
2024-02-12−21,364→ 0 totalExercise: $0.00→ Common Stock (21,364 underlying) - Disposition to Issuer
Common Stock
2024-02-12−21,039→ 0 total - Disposition to Issuer
Stock Option (Right to Buy)
2024-02-12−35,871→ 0 totalExercise: $4.55Exp: 2030-02-07→ Common Stock (35,871 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2024-02-12−121,905→ 0 totalExercise: $7.69Exp: 2031-02-05→ Common Stock (121,905 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2024-02-12−115,273→ 0 totalExercise: $5.32Exp: 2032-02-04→ Common Stock (115,273 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2024-02-12−140,400→ 0 totalExercise: $4.66Exp: 2033-02-03→ Common Stock (140,400 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2024-02-12−12,666→ 0 totalExercise: $2.68Exp: 2026-09-30→ Common Stock (12,666 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2024-02-12−1,333→ 0 totalExercise: $5.75Exp: 2026-06-01→ Common Stock (1,333 underlying) - Disposition to Issuer
Restricted Stock Unit
2024-02-12−48,360→ 0 totalExercise: $0.00→ Common Stock (48,360 underlying)
Footnotes (4)
- [F1]This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated November 30, 2023, by and among the Issuer, AbbVie Inc., a Delaware corporation ("AbbVie"), Athene Subsidiary LLC, a Delaware limited liability company and wholly owned subsidiary of AbbVie ("Intermediate Sub"), and Athene Merger Sub Inc., a Massachusetts corporation and wholly owned subsidiary of Intermediate Sub ("Purchaser"), pursuant to which Purchaser merged with and into the Issuer with the Issuer continuing as the surviving corporation (the "Merger"). At the effective time of the Merger (the "Effective Time"), each share of common stock, par value $.01 per share, of the Issuer (the "Common Stock"), that was issued and outstanding immediately prior to the Effective Time was converted into the right to receive an amount in cash equal to $31.26, without interest (the "Merger Consideration").
- [F2]Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock ("Stock Option") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option.
- [F3]Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit ("RSU") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such RSU, an amount in cash (less any applicable withholding taxes) equal to (i) the number of shares of Common Stock subject to such RSU immediately prior to the Effective Time, multiplied by (ii) the Merger Consideration.
- [F4]Pursuant to the Merger Agreement, at the Effective Time, each RSU granted on or after the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was converted into a grant of restricted stock unit awards in respect of a number of shares of AbbVie common stock equal to the number of shares of Common Stock underlying such RSU as of immediately prior to the Effective Time multiplied by 0.18, and otherwise with the same terms and conditions that were applicable immediately prior to the Effective Time.
Documents
Issuer
ImmunoGen, Inc.
CIK 0000855654
Entity typeother
Related Parties
1- filerCIK 0001510720
Filing Metadata
- Form type
- 4
- Filed
- Feb 11, 7:00 PM ET
- Accepted
- Feb 12, 4:41 PM ET
- Size
- 33.7 KB